A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma
Resistance to these agents develops frequently, and their use is often limited by intolerance.05/01/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology